Morningside Group is a global investment firm engaged in both private equity and venture capital investments.
| Company | Date | Round | Size | Participants |
| GlySure | 11/12 | Series C | $13.6M | 4 |
| Advanced Cell Diagnostics | 11/12 | Series B | $12M | 2 |
| Genocea Biosciences | 10/12 | Series C | $30M | 10 |
| Synchroneuron | 2/12 | Series A | $6M | 1 |
| GlySure | 1/12 | Series C | £7M | 4 |
| NuCana BioMed | 11/11 | Series A | £6.74M | 3 |
| Wuhan Kindstar Diagnostics | 6/11 | Series B | $11M | 4 |
| Indel Therapeutics | 4/11 | Series B | $1.4M | 3 |
| Aduro BioTech | 4/11 | Series B | $19.3M | 1 |
| Clean Membranes | 1/11 | Series A | 1 | |
| Genocea Biosciences | 1/11 | Series B | $35M | 9 |
| Cylene Pharmaceuticals | 9/10 | Series D | $12M | 6 |
| Green Biologics | 7/10 | Series B | $6.1M | 4 |
| Bioscale | 6/10 | Series D | $25M | 4 |
| Liquidia Technologies | 1/10 | Series C | $20M | 5 |
| ByRead | 12/09 | Series B | $3M | 2 |
| BioVex | 11/09 | Series F | $30M | 5 |
| Advanced Cell Diagnostics | 9/09 | Series A | $5.4M | 1 |
| Traversa Therapeutics | 4/09 | Series B | $5M | 2 |
| ViOptix | 1/08 | Series D | $12.2M | 4 |
| Procarta Biosystems | 11/07 | Venture Round | £730k | 3 |
| 51hejia.com | 7/07 | Series B | $10M | 2 |